Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
-
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
-
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
-
Opus Genetics Announces $23 Million Registered Direct Offering
-
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness
-
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
-
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
-
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
-
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)